Search For "biocon"
New insulin glargine injection launched in US for diabetes patients
Updated : 5 years, 6 months ago IST
Bengaluru (Karnataka) [India], Aug 31 (ANI): Biocon Biologics and Mylan on Monday announced the US launch of Semglee™ (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and paediatric patients with type 1 diabetes a
Read More
Tata Capital to pick minority stake in Biocon Biologics for Rs 225 cr
Updated : 5 years, 7 months ago IST
Bengaluru (Karnataka) [India], July 31 (ANI): Private equity major Tata Capital Growth Fund will pick up 0.85 per cent stake in the biologics arm of biopharmaceutical major Biocon for Rs 225 crore.
Read More
Biocon stock falls 2 pc after 28 pc fall in Q1 net profit
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Shares of Biocon Ltd fell by nearly 2 per cent on Friday morning after the biopharmaceutical major posted 28 per cent fall in its June quarter (Q1 FY21) net profit at Rs 149 crore.
Read More
ICMR validates, approves 2 more antigen test kits
Updated : 5 years, 7 months ago IST
New Delhi [India], July 22 (ANI): The Indian Council of Medical Research (ICMR) has validated and approved two more antigen test kits.
Read More
Biocon Biologics and Voluntis join hands for global collaboration on dig
Updated : 5 years, 7 months ago IST
Bengaluru (Karnataka) [India], July 21 (ANI): Biocon Biologics India Limited, a fully integrated 'pure-play' biosimilars company, a subsidiary of Biocon Ltd. on Tuesday announced a global collaboration agreement between Biocon Biologics' subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis to
Read More
Biocon's drug Itolizumab gets DCGI nod for use in moderate to severe Covid
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 11 (ANI): Biopharmaceutical major Biocon Ltd said on Saturday it has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5ml solution for emergency use in India for the treatment of cytokine release syndr
Read More
DCGI approves Itolizumab injection for restricted emergency use on COVID-1
Updated : 5 years, 8 months ago IST
New Delhi [India], July 11 (ANI): The Drug Controller General of India (DCGI) granted its permission to Itolizumab injection for the restricted emergency use on COVID-19 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to virus.
Read More
Biocon, DKSH collaborate to commercialise 7 generic formulations in SE Asi
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], June 22 (ANI): Biopharmaceutical major Biocon Ltd and Swiss market expansion services group Diethelm Keller Siber Hegner (DKSH) said on Monday their subsidiaries have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic
Read More
Kiran Mazumdar Shaw wins EY World Entrepreneur of the Year 2020 Award
Updated : 5 years, 9 months ago IST
Bengaluru (Karnataka) [India], June 5 (ANI): Biocon Ltd said on Friday that its Executive Chairperson Kiran Mazumdar Shaw has been named the EY World Entrepreneur of the Year 2020 (WEOY) at a virtual award ceremony held on late Thursday.
Read More
Banking sector needs recapitalisation of Rs 4 lakh crore: Uday Kotak
Updated : 5 years, 9 months ago IST
New Delhi [India], June 2 (ANI): Industry leaders said on Tuesday that the banking and financial sectors need structural reforms to propel economic growth as the country aspires to become self-reliant in the face of coronavirus crisis and enters the 'Unlock Phase 1.'
Read More
Biocon Biologics appoints M B Chinappa as new CFO
Updated : 6 years, 2 months ago IST
Bengaluru (Karnataka) [India], Jan 7 (ANI): Biocon Ltd has appointed M B Chinappa as the Chief Financial Officer of its subsidiary Biocon Biologics India Ltd.
Read More
True North to invest Rs 536 crore in Biocon Biologics for 2.4 pc stake
Updated : 6 years, 2 months ago IST
Bengaluru (Karnataka) [India], Jan 6 (ANI): Biopharmaceuticals major Biocon said on Monday the board of its subsidiary Biocon Biologics has approved a primary equity investment by True North which will invest Rs 536.25 crore to pick 2.44 per cent minority stake in the biosimilars business.
Read More